Trevena Regains Compliance with Nasdaq Listing Requirements
CHESTERBROOK, Pa., Nov. 29, 2022 (GLOBE NEWSWIRE) — Trevena, Inc. (Nasdaq:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has received notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (Nasdaq) by letter dated November 28, 2022 informing Trevena that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The Company maintained a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days and, as a result of regaining compliance, its common stock will continue to be listed on the Nasdaq Capital Market.
Related news for (TRVN)
- Trevena Publicizes TRV045 Preclinical Data
- Trevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercise
- Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise
- Trevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meeting
- Trevena Announces Poster Presentations of TRV045 Nonclinical Epilepsy Data, and OLINVYK Clinical Neurocognitive and GI Data, at Recent Medical Meetings